The efficacy of combining HDACi with PD-1 inhibitors has been evaluated in multiple preclinical cancer models, including melanoma, ovarian cancer, breast cancer, and lung cancer, showing great promise (136, 182, 183). Here, PDCD1 is linked to breast carcinoma.